Ebola Virus Clinical Trial
Official title:
A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.
Between 1994 and the present, there have been many Ebola viruses (EBOV) outbreaks affecting
mostly central Africa. However, the 2014 West African outbreak significantly exceeds all
previous outbreaks in geographic range, number of individuals affected and in disruption of
typical activities of civil society.
This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a
live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope
glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola
(VSVΔG-ZEBOV also known as V920 and BPSC-1001).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02271347 -
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
|
Phase 2 | |
| Completed |
NCT02269423 -
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
|
Phase 1 | |
| Completed |
NCT03719586 -
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT04041570 -
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02344407 -
Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
|
Phase 2 |